Alogliptin / Pioglitazone Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 12.5 mg / 30 mg, 25 mg / 15 mg, 25 mg / 30 mg, 25 mg / 45 mg
Reference Brands: Oseni (USA), Incresync(EU)
Category: Diabetes
Alogliptin + pioglitazone tablets combine a DPP-4 inhibitor with a glitazone in one daily tablet for type 2 diabetes. Strengths range from 12.5/15 mg to 25/45 mg. Reference brands are Oseni (US) and Incresync (EU). Pioglitazone can cause fluid retention, so it is not used in heart failure. Patent status differs by country, so we confirm what can lawfully be supplied to your destination before quoting.
Manufacture or export Alogliptin / Pioglitazone Tablet? List it or send an offer →
Product Description:
Alogliptin / Pioglitazone is a fixed-dose combination anti-diabetic medication designed to improve glycemic control in adults with type 2 diabetes mellitus (T2D). Type 2 diabetes is a progressive condition that often requires sequential additions of therapy to maintain blood glucose levels. By combining two complementary mechanisms of action, this combination provides an effective and convenient treatment option. Alogliptin, a dipeptidyl peptidase-4 (DPP‑4) inhibitor, increases incretin activity, enhancing insulin release and suppressing glucagon secretion in a glucose-dependent manner. Pioglitazone, a thiazolidinedione, improves insulin sensitivity in peripheral tissues, helping to lower blood glucose and support long-term glycemic control.
Fixed-dose combinations like Alogliptin / Pioglitazone simplify therapy regimens, which can enhance medication adherence and improve patient outcomes. The combination is marketed globally under brand names such as Oseni and Incresync. Use of this therapy should be guided by individual patient needs, considering factors such as renal function, cardiovascular status, and potential adverse effects. Regular monitoring and collaboration with healthcare professionals ensure safe and effective management of type 2 diabetes with this combination therapy.
Alogliptin / Pioglitazone Tablet — third party manufacturing & bulk supply
Alogliptin / Pioglitazone Tablet is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Alogliptin / Pioglitazone Tablet is supplied as Tablets — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Alogliptin / Pioglitazone Tablet listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Alogliptin / Pioglitazone Tablet →Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.
Frequently Asked Questions
Alogliptin / Pioglitazone is used to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin increases incretin activity to enhance insulin release and suppress glucagon levels, while pioglitazone improves insulin sensitivity in peripheral tissues, helping to lower blood glucose levels when diet and exercise alone are not sufficient.
This combination contains two active ingredients: alogliptin benzoate, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor, and pioglitazone hydrochloride, a thiazolidinedione that increases insulin sensitivity.
The combination product is marketed under brand names such as Oseni and Incresync in various regions.
It is manufactured by multiple pharmaceutical companies globally, including generic manufacturers approved in different countries.
The generic name is alogliptin and pioglitazone.
Common brand names include Oseni and Incresync.
Alogliptin / Pioglitazone is manufactured in several countries, including India, the USA, and European nations, by approved pharmaceutical manufacturers.
12.5/15, 12.5/30, 12.5/45, 25/15, 25/30 and 25/45 mg tablets, taken once daily.
People with heart failure (NYHA class III–IV), active bladder cancer or significant liver disease, because of pioglitazone.
Generic versions exist in some markets; patent status varies, so we confirm it for your destination.
Related Products
Alogliptin/Metformin
Strength:
12.5mg+500mg / 12.5mg+850mg / 12.5mg+1000mg
Form: Tablets
Reference Brands: Kazano (USA), Vipdomet (EU)
View Details
Nph Human Insulin (Rdna Origin)
Strength:
40U/ml, 100U/ml
Form: Injection
Reference Brands: Humulin N (USA), Novolin N (USA), Insulatard (EU/UK)
View Details
Alogliptin Tablet
Strength:
6.25 mg, 12.5 mg, 25 mg
Form: Tablet
Reference Brands: Nesina (USA/EU), Kazano (USA), Vipidia (EU)
View Details
Exenatide
Strength:
5 mcg/1.2 mL, 10 mcg/2.4 mL
Form: injection (prefilled syringe)
Reference Brands: Byetta (USA/EU)
View Details
Albiglutide
Strength:
30mg, 50mg
Form: injection (prefilled syringe)
Reference Brands: Tanzeum (USA), Eperzan (EU/UK)
View Details
Insulin Glulisine
Strength:
100 IU/mL
Form: injection (prefilled syringe)
Reference Brands: Apidra (USA/EU)
View Details
Usually answered within 48 hours | GMP documents shared before you commit
